The purpose of this study is to determine whether the drug that produce red blood cells is effective in the prevention of kidney dysfunction after coronary angiography in patients with chronic kidney disease.
Use of radiocontrast agent is inevitable in computed tomography or angiography. However, contrast agent can aggravate kidney function. Contrast-induced nephropathy (CIN) refers to the clinical situation where decreased kidney function after use of contrast. CIN is the 3rd most common cause of acute kidney injury in the hospitals. There are a lot of reports that death rate is increased in patients with CIN. Erythropoietin is an agent that treat anemia. It also has been reported to have a tissue-protective effect in the animal experiments. In this study, we hypothesized that erythropoietin can reduce the incidence of CIN in patients with chronic kidney disease undergoing coronary angiography.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
80
Infusion of darbepoetin-α 1.5 μg/kg will be performed 1 hour before angiography
Infusion of isotonic saline will be performed 1 hour before angiography
Seoul National University Bundang Hospital,
Seongnam, South Korea
incidence of contrast-induced nephropathy (CIN)
a greater than 25 percent increase in serum Cr or an absolute increase in serum Cr of 0.5 mg/dL within 48 hours after using the contrast agent
Time frame: 48 hours
maximum difference in Cr levels before and after CAG(coronary angiography) or PCI(percutaneous coronary intervention)
the maximum difference in Cr levels before and after CAG or PCI, the incidence of AKI requiring renal replacement therapy, length of hospital stay, mortality, myocardial infarction, revascularization, and the occurrence of stroke
Time frame: 1 month after the intervention
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.